CINPHA Share Price Performance
SEK 0
-15.30 (-100.00%)
Price SEK 0
Fair ValueSEK 55.00
Share Pricen/a
Cinclus Pharma Holding AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
CINPHA Community Narratives
AN
Fair Value SEK 55 69.2% undervalued intrinsic discount
Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value SEK 75 77.4% undervalued intrinsic discount
Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value SEK 50 66.1% undervalued intrinsic discount
Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Advancing Late-Stage GERD Studies Will Drive Substantial Long-Term Upside
Key Takeaways Innovative drug formulation, strong market demand, and strategic partnerships position Cinclus Pharma for significant revenue and margin growth in both domestic and international markets. Retention of global commercial rights enables flexible licensing or direct launch strategies, supporting long-term earnings potential through multiple income streams.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
SEK 55
69.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
62.75% p.a.
Profit Margin
24.24%
Future PE
58.04x
Price in 2028
SEK 63.06
Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care
Key Takeaways Rapid adoption of Cinclus Pharma's therapy, plus strategic U.S. deals, could deliver accelerated revenue growth, robust earnings, and significant cash generation above market expectations. Favorable market trends, specialty biotech efficiency, and industry consolidation position Cinclus for premium pricing, sustained profitability, and a major increase in valuation potential.Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 75
77.4% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
104.38% p.a.
Profit Margin
22.63%
Future PE
53.32x
Price in 2028
SEK 85.62
Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism
Key Takeaways Heavy dependence on a single late-stage asset exposes Cinclus Pharma to significant clinical, regulatory, and competitive risks that may limit future earnings and margin growth. Sustained R&D expenses, complex approval processes, and increasing pricing pressure from generics and large pharmaceutical groups could compress profitability and constrain long-term shareholder returns.Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
SEK 50
66.1% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
44.05% p.a.
Profit Margin
22.63%
Future PE
101.51x
Price in 2028
SEK 57.08
Trending Discussion
Recently Updated Narratives
AN
CINPHA: FDA Guidance Will Support Pivotal Phase III Trial Momentum
Fair Value: SEK 55 69.2% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Clinical And Regulatory Obstacles Will Challenge Gastroenterology Prospects Despite Optimism
Fair Value: SEK 50 66.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care
Fair Value: SEK 75 77.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cinclus Pharma Holding AB (publ) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 16, 2026
- -3.95
- 100.00%
- -320.12%
- 0%
About CINPHA
- Founded
- 2014
- Employees
- 21
- CEO
- WebsiteView website
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
